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Background: The Chinese medicine formulation ISF-1 (also known as Bu-Yang-Huan-Wu-Tang) for post-stroke
rehabilitation could increase the expression of growth-regulating protein follistatin by approximately 4-fold. This
study aims to identify the active compounds of ISF-1 for the induction of follistatin expression.
Methods: Active compounds in ISF-1 responsible for induction of follistatin were identified by a bioactivity-guided
fractionation procedure involving liquid-liquid extraction, HPLC separation and RT-PCR detection. The aqueous
extracts of seven ISF-1 ingredients including Semen Persicae (Tao Ren) and the S. Persicae-derived fractions were
assayed for the induction of follistatin mRNA expression in human hepatocarcinoma HepG2 cells by RT-PCR. The
concentrations of isolated compounds were proportionally normalized to the reported IC50 concentration (5.8 mg/mL)
of the formulation ISF-1 in HepG2. The active fractions were characterized by reverse-phase HPLC on a C18 column and
identified by mass spectrometry.
Results: Three ingredients of ISF-1, namely S. Persicae (Tao Ren), Pheretima (Di Long), and Flos Carthami (Hong Hua),
induced the expression of follistatin mRNA. Among these, the ingredient S. Persicae were the most active, and
amygdalin from S. Persicae extract was identified as a novel follistatin inducer. Amygdalin stimulated the growth
of skeletal muscle cell line C2C12 cells in a concentration-dependent manner.
Conclusions: Amygdalin isolated from S. Persicae extract in ISF-1 through a bioactivity-guided fractionation procedure
induced the expression of follistatin in HepG2 and C2C12 cell lines.Background
Stroke causes severe disability and mortality worldwide,
characterized by dramatic structural and metabolic changes
in skeletal muscle that can lead to post-stroke sarcopenia
[1,2]. Recombinant tissue plasminogen activator is the only
FDA approved drug for the treatment of acute ischemic
stroke but is limited by a narrow therapeutic window and
the ineffectiveness for post-stroke recovery [3,4].
Myostatin has emerged as a molecular target for thera-
peutic intervention [5]. Both pharmacological inhibition
and genetic targeting of myostatin were under evaluation
for treating sarcopenia [6-9]. Follistatin is an autocrine
glycoprotein with strong ability to antagonize different
members of the TGF-β superfamily, such as activin and* Correspondence: jrong@hkucc.hku.hk
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unless otherwise stated.myostatin [10-13], regulating cell proliferation, cell differen-
tiation, inflammatory responses, and embryogenesis
[11,14-16]. Follistatin has been recently evaluated as a treat-
ment for fibrotic diseases in animal models aa [14,17,18].
However, as an endogenous antagonist of myostatin, follis-
tatin acts as a negative regulator of muscle growth [13].
Transfection of follistatin cDNA construct for increasing
follistatin protein expression could increase muscle mass in
experimental animals [6,7,19]. Therefore, pharmacological
induction of follistatin expression might serve as a new
strategy for the treatment of post-stroke and age-related
sarcopenia.
The Chinese medicine formulation ISF-1 (also known as
Bu-Yang-Huan-Wu-Tang), was used for post-stroke re-
habilitation. The formulation consists of seven ingredients,
including Radix Astragali (Huang Qi), Radix Angelicae
Sinensis (Dang Gui), Radix Paeoniae Rubra (Chi Shao),
Rhizoma Chuanxiong (Chuan Xiong), Flos Carthami (Hongd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[20,21]. We previously profiled the cellular responses to for-
mulation ISF-1 in human HepG2 cells by a genome-wide
biological response fingerprinting (BioReF) approach [20],
and developed a bioactivity-guided fractionation procedure
involving liquid-liquid extraction, HPLC separation and
RT-PCR detection to identify the active compounds in-
volved in the induction of heme oxygenase-1 and leukotri-
ene B4 12-hydroxydehydrogenase [22,23].
This study aims to identify the active compounds of
ISF-1 for the induction of follistatin expression.
Methods
Cell culture and reagents
The human hepatocellular carcinoma cell line HepG2
[ATCC No. HB-8065] and mouse skeletal muscle cell
line C2C12 [ATCC No. CRL-1722] were obtained from
American Type Culture Collection (USA). The cells
were cultured in Dulbecco’s modified Eagle’s medium
supplemented with 10% (v/v) fetal bovine serum and 1%
penicillin/streptomycin (Invitrogen, USA) at 37°C in a
humidified atmosphere containing 5% CO2 and 95% air.
All chemicals were obtained from Sigma-Aldrich Co.
(USA), unless otherwise indicated. Dried herbal ex-
tracts, R. Astragali (Cat No. 1008; Batch No. A090611-
01), S. Persicae (Cat No. 1106; Batch No. A06273-01),
Pheretima (Cat No. 1118, Batch No. A06314-01), F.
Carthami (Cat No. 1297, Batch No. A04579-02), R.
Sinensis (Cat No. 1187, Batch No. A00397-03), R. Rubra
(Cat No. 1059, Batch No. A06001-01), and R. Chuanxiong
(Cat No. 1019; A06430-01), were purchased from Nong’s
Pharmaceutical Ltd. (Hong Kong). Oligonucleotide
primers specific for follistatin and glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) were purchased
from the Centre for Genomic Sciences, The University
of Hong Kong.
Apparatus and chromatographic conditions
HPLC analysis was performed on an Alltima™ HP C18
column (250 × 4.6 mm, 5 μm, Alltech, USA) under the
control of a HPLC system (Waters, USA) equipped with
a Waters 996 Model photodiode array detector (DAD), a
Waters 600S Model system controller, and a gradient
generator. The column was run in a gradient mobile
phase generated by mixing an aqueous solution (A) and
acetonitrile (B). The samples were eluted with 5% B for
5 min, followed by a linear gradient up to 95% B over a
period of 50 min. The flow rate was set at 1 mL/min
and the column temperature was maintained at 25°C.
For analysis of the fifth fraction (fraction F5) and the
spiked-in amygdalin standard, the samples were eluted
with aqueous solution A containing 9% acetonitrile and
9% methanol. The UV absorbance was recorded over the
range of 200–400 nm.Assay of herbal extracts for induction of follistatin
Dried powder samples of aqueous herbal extracts (R.
Astragali, S. Persicae, Pheretima, F. Carthami, R. Sinensis,
R. Rubra, and R. Chuanxiong) were purchased from
Nong’s Pharmaceutical Ltd. (Hong Kong). For herbal ex-
tract preparation, the dried powder of each herbal extract
(100 mg) was dissolved in 1 mL of Milli Q water produced
by Milli Q Synthesis A10 Water Purificaiton System
(EMD Millipore, Germany) at 80°C for 30 min, with vor-
texing every 10 min. After cooling to room temperature,
the insoluble materials were removed by centrifugation at
12,000 rpm on an Eppendorf 5424 microcentrifuge
(Eppendorf AG, Germany) for 10 min. The supernatant
was recovered and sterilized by passage through a syringe
filter with a 0.22-μm (Pall, New York, USA) membrane.
For assays of follistatin induction, HepG2 cells were treated
for 24 h with the supernatants of the individual herbal
extracts at the following concentrations: R. Astragali,
5.18 mg/mL; S. Persicae, 0.13 mg/mL; Pheretima, 0.13 mg/
mL; F. Carthami, 0.13 mg/mL; R. Sinensis, 0.26 mg/mL;
R. Rubra, 0.19 mg/mL; R. Chuanxiong, 0.13 mg/mL. The
expression of follistatin was detected by RT-PCR and ana-
lyzed by 1% agarose gel electrophoresis.Bioactivity-guided fractionation of Semen Persicae extract
The dried S. Persicae extract (50 g) was resuspended in
250 mL of Milli Q water and heated at 80°C for 1 h. Fol-
lowing precipitation with 70% ethanol overnight and re-
moval of insoluble materials by centrifugation at 4000 ×
g for 15 minutes, the supernatant (A) was collected and
sequentially extracted three times with 250 mL of ethyl
acetate (EA fraction) and n-butanol (n-butanol fraction).
The solvents for each extraction were finally removed by
a rotary evaporator (Tokyo Rikakikai, Japan) under vac-
uum. The dried residues from each preparation were
dissolved in dimethyl sulfoxide, filtered through a 0.22-
μm membrane (Pall, USA), and subjected to the follista-
tin induction assay in HepG2 cells.
For isolation of the active compounds, the n-butanol
fraction was further separated by semi-preparative
reverse-phase HPLC on an Alltima C-18 column
(250 × 10.0 mm, 5 μm, Alltech, USA). The column was
run in a gradient mobile phase generated by mixing an
aqueous solution (A) and acetonitrile (B). The samples
were eluted with 5% B for 5 min, followed by a linear
gradient elution up to 95% B over a period of 50 min.
The flow rate was set at 3 mL/min and the column
temperature was maintained at 25°C. The UV absorb-
ance was monitored on a HPLC UV detector (Waters,
USA) over the wavelength range of 200–400 nm.
Eleven fractions were collected and assayed for follista-
tin induction. Finally, each active compound was puri-
fied as a single peak in the HPLC profile.
Figure 1 Identification of the active ingredients for induction of follistatin expression. HepG2 cells were treated with different herbal
extracts, R. Astragali, R. Chuanxiong, F. Carthami, Pheretima, R. Sinensis, R. Rubra, and S. Persicae, for 24 h. Subsequently, the expression of follistatin mRNA
was detected by RT-PCR and 1 % agarose gel electrophoresis of the PCR products. +, treatment with selected herbal extract; −, no treatment with
selected herbal extract.
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The HPLC fraction containing the active compound was
analyzed on a Varian MicroSorb C18 column (2 ×
150 mm) (Agilent, USA) at a flow rate of 0.8 mL/min
under the control of a LC-MS system (Waters, USA)
equipped with a 1525 Separations Module and a WatersFigure 2 Schematic illustration of the bioactivity-guided fractionation
S. Persicae extract. The n-butanol extract was separated by semi-preparat
semi-quantitative RT-PCR for follistatin mRNA induction in HepG2 cells.2998 DAD Unit (Waters, USA). The mobile phase com-
positions were water with 0.3% (v/v) formic acid (A) and
acetonitrile (B). The gradient was set as follows: 0–
8 min, 5- 50% B; 8–10 min, 50% B; 12–15 min, 95% B. The
flow rate was constant at 0.8 mL/min and the column
temperature was maintained at 20°C. The injection volumeprocedure for identification of the active compound from
ive RP-HPLC on a C18 column. All of the fractions were analyzed by
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pole mass spectrometer 3200 QTRAP® system (ABI/Sciex,
USA) equipped with an ESI-Turbo V™ source operating in
the positive ionization mode under the control of an Ana-
lyst v1.4.2 data system (Applied Biosystems/MDS Sciex,
Canada). The mass spectrometry analyses were performed
under the following conditions: N2 drying gas, 10 L/min;
capillary voltage, 20 V; nebulizer pressure, 30 psi; ion spray
voltage, 4 kV; and capillary temperature, 325°C.
RT-PCR detection
Following treatment with herbal extracts or isolated
fractions, total RNA was isolated from the cells by TRI-
zol reagent (Invitrogen, USA). The mRNAs were con-
verted into cDNAs by Moloney Murine Leukemia Virus
(M-MuLV) reverse transcriptase kit (Fermentas, USA).
Human and mouse follistatin mRNAs were detected byFigure 3 RT-PCR assay for induction of follistatin expression. (A) Assay
cells were treated with S. Persicae extract at the indicated concentrations a
mRNA was detected by RT-PCR. S/N, supernatant; EA, ethyl acetate. (B) HPL
separated by semi-preparative RP-HPLC on a C18 column into 11 fractions.
induction of follistatin mRNA expression.PCR using specific oligonucleotide primers as follows:
human follistatin mRNA (NM_006350): sense, 5'-GTT
TTCTGTCCAGGCAGCTCCACA-3', antisense, 5'-GC
AAGATCCGGAGTGCTTTACTTCCA-3'; mouse follista-
tin mRNA (NM_008046): sense, 5′-CTCTTCAAGTGGA
TGATTTTC-3', antisense, 5′-ACAGTAGGCATTATTG
GTCTG-3′. As an internal control, GAPDH mRNA
(NM_001256799) was also detected using specific oligo-
nucleotide primers: sense, 5'-CAAGGTCATCCATGAC
AACTTTG-3', antisense, 5'-GTCCACCACCCTGTTGC
TGTAG-3'. The PCR amplifications were performed as
follows: denaturation at 94°C for 3 min; 30 cycles of ampli-
fication at 94°C for 30 s, 65°C (human follistatin), 50°C
(mouse follistatin), or 55°C (GAPDH) for 30 s, and 72°C
for 30 s; and extension at 72°C for 10 min. The PCR prod-
ucts were analyzed by electrophoresis in a 1.0% agarose
gel containing Gel Red and visualized under UV light by as of S. Persicae extract and liquid-liquid extraction products. HepG2
nd S. Persicae-derived fractions for 24 h, and the expression of follistatin
C separation of the n-butanol extract. The n-butanol extract was
(C) Assays of HPLC fractions. The HPLC fractions were assayed for
Figure 4 Chemical characterization of fraction F5. (A) LC-MS analysis of fraction F5. Positive ESI-MS m/z signals are shown. The chemical structure of
amygdalin was generated by ACD/Chem Sketch software (http://www.acdlabs.com/resources/freeware/chemsketch/). (B) HPLC verification of amygdalin
as the active compound. The fraction F5, amygdalin standard, and F5-amygdalin mixture were sequentially analyzed by reverse-phase HPLC on a C18
column under the same conditions. (C) RT-PCR verification of commercial amygdalin for induction of follistatin mRNA. HepG2 cells were treated with
commercial amygdalin at the indicated concentrations for 24 h. The expression of follistatin mRNA was detected by RT-PCR.
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EtBr-stained gel bands was obtained by densitometric ana-
lysis using software Quantity One (Bio-Rad, USA). After
normalization against housekeeping gene GAPDH, the
mean values of follistatin induction relative to the un-
treated control were calculated based on the results of
three independent experiments.
Cell viability assay
Cell viability was evaluated by a standard colorimetric
assay as previously described [24]. Briefly, C2C12 cells
(0.4 × 104 cells/100 μL) were seeded in a 96-well micro-
plate and treated with amygdalin at concentrations of 0–
25 μM for 24 or 48 h. At the end of the treatment, the
cell monolayers were incubated with 3-[4,5-dimethyl-
thiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) so-
lution (0.5 mg/mL) in phosphate-buffered saline for 4 h.
The formation of purple formazan was measured in rela-
tion to the absorbance at 570 nm by a microplate reader
(Bio-Rad, USA). The cell viability was presented as a per-
centage relative to that of vehicle-treated control cells.
Statistical analysis
The results were presented as means ± SD from three in-
dependent experiments. Statistical analysis was performed
by two-tailed unpaired Student’s t-test with SPSS 13.0 soft-
ware (SPSS, Chicago, USA). A P value < 0.05 was consid-
ered as statistically significant.Results
Screening of herbal extracts for induction of follistatin
expression
We treated HepG2 cells with aqueous extracts of the indi-
vidual herbs for 24 h. Follistatin induction was subsequently
detected by RT-PCR using specific primers. Three herbal
extracts (S. Persicae, Pheretima, and F. Carthami) induced
the expression of follistatin mRNA, while the expression of
the housekeeping gene GAPDH was not affected (Figure 1).
The S. Persicae extract showed the strongest activity for in-
creasing follistatin mRNA expression among the three ex-
tracts. Thus, the S. Persicae extract was selected for further
characterization by bioactivity-guided fractionation.
Bioactivity-guided fractionation of S. Persicae extract for
follistatin induction
We developed a simple bioactivity-guided fractionation pro-
cedure to isolate the active compounds from S. Persicae ex-
tract (Figure 2). The dried aqueous herbal extract purchased
from Nong’s Pharmaceutical Ltd. and was verified to have
activity in follistatin induction. Briefly, HepG2 cells were
treated with S. Persicae extract at contractions of 0, 0.125,
0.25, 0.5, 0.75, and 1.0 mg/mL. Subsequent RT-PCR analyses
of follistatin mRNA confirmed S. Persicae extract induced
the expression of follistatin mRNA in a concentration-
dependent manner (Figure 3A). For bioactivity-guided frac-
tionation, the dried S. Persicae extract was re-extracted and
then precipitated with ethanol. The resulting mixture was
Yang et al. Chinese Medicine 2014, 9:23 Page 6 of 8
http://www.cmjournal.org/content/9/1/23separated by centrifugation into two parts, a supernatant (S/
N) and a pellet. The supernatant was sequentially extracted
with ethyl acetate (EA) and n-butanol, giving rise to another
three fractions, EA extract, n-butanol extract, and H2O
phase. All of the fractions were evaluated for induction of
follistatin mRNA. The n-butanol extract effectively induced
the expression of follistatin mRNA (Figure 3A).
Amygdalin in the n-butanol extract of S. Persicae is a
novel inducer of follistatin
We separated the n-butanol extraction into 11 fractions
by HPLC on a C18 column to isolate the active compound
from the n-butanol extract of S. Persicae (Figure 3B). All
of the fractions were assessed for induction of follistatin
mRNA. Fraction F5 showed the strongest activity in indu-
cing follistatin mRNA expression, while fractions F2 and
F9 also showed some activity (Figure 3C). Fraction F5 was
further analyzed by LC-MS. The positive ESI-MS m/z
spectrum of fraction F5 contained four important signals
at 458 [M+H+], 475 [M], 480 [M+Na+], and 937 [2 M+
Na+] (Figure 4A), suggesting the presence of amygdalin in
this fraction [25].
We compared the retention times of fraction F5 and an
amygdalin standard in the HPLC profile to verify the effectFigure 5 Effect of amygdalin on follistatin expression and cell proli
mRNA by amygdalin. Mouse skeletal muscle C2C12 cells were treated w
follistatin mRNA were determined by RT-PCR. (B) Stimulation of skeletal
amygdalin at the indicated concentrations for 24 or 48 h. The viable cell
means ± SD from three independent experiments. *P < 0.05, **P < 0.01, aof amygdalin on follistatin mRNA expression. Fraction F5
was confirmed to elute with the same pattern as the com-
mercial amygdalin standard. We observed two closely
eluted peaks for both fraction F5 and the amygdalin stand-
ard (Figure 4B). Next, we clarified whether the commercial
amygdalin standard could induce follistatin mRNA. As ex-
pected, the commercial amygdalin standard effectively
induced follistatin mRNA expression in a concentration-
dependent manner (Figure 4C). LC-MS analyses of
fractions F2 and F9 could not identify any chemical
compounds reported by others [26,27].
Effects of amygdalin on the expression of follistatin and
proliferation of skeletal muscle C2C12 cells
We treated the cells of mouse skeletal muscle cell line
C2C12 with amygdalin at various concentrations (0–
25 μM) to characterize whether amygdalin could induce
follistatin mRNA expression in skeletal muscle cells.
The expression of follistatin mRNA was detected by RT-
PCR using specific primers. Amygdalin effectively induced
the expression of follistatin mRNA in a concentration-
dependent manner (Figure 5A). We further investigated
whether amygdalin could accelerate the growth of skeletal
muscle cells. We treated C2C12 cells with amygdalin at theferation in skeletal muscle C2C12 cells. (A) Induction of follistatin
ith amygdalin at the indicated concentrations for 24 h. The levels of
muscle cell growth by amygdalin. C2C12 cells were treated with
s were measured by a standard MTT assay. The values represent
mygdalin treatment vs. control.
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able cells were determined by a standard MTT assay.
Amygdalin was confirmed to stimulate the growth of skel-
etal muscle cell line C2C12 cells in a concentration- and
time-dependent manner (Figure 5B).
Discussion
The genome-wide BioReF approach not only helps in the
selection of candidate genes for complex herbal medicines
in a bias-free manner, but also enables rapid identification
of the corresponding active compounds [20,22,23]. Subse-
quent bioactivity-guided fractionation could be performed
on a relatively small scale to identify the active compounds
that were actually responsible for the specific bioactivity of
the parent herbal extracts. In the present study, we investi-
gated the active compounds for the induction of follistatin,
from a previous BioReF profile [20]. We developed a
bioactivity-guided fractionation procedure to identify the
active compound from formulation ISF-1 involved in the
induction of follistatin expression. We identified three
herbs, S. Persicae, Pheretima, and F. Carthami, as the ac-
tive ingredients in HepG2 cells. Amygdalin was identified
from the S. Persicae extract as an inducer of follistatin.
Amygdalin existed in two forms, D-amygdalin and neoa-
mygdalin [28,29]. The two closely eluted peaks in the
HPLC profiles of fraction F5 and the amygdalin standard
were observed, which might reflect the two forms of
amygdalin. However, we cannot rule out the possibility
that similar or different active compounds might be
present in other active fractions (e.g., fractions F2 and F9).
S. Persicae was an anticoagulant, antiphlogistic, and ano-
dyne in Chinese medicine [30,31]. However, little was
known about the role of S. Persicae in the treatment of
post-stroke disorders. Several myostatin inhibitors, including
myostatin propeptide, monoclonal antibodies, follistatin,
and follistatin-like proteins, have been evaluated for the
treatment of muscle-wasting disorders [7,13,32-34]. While
these studies used recombinant follistatin as myostatin in-
hibitor, the present study demonstrated that amygdalin in S.
Persicae could induce the expression of follistatin mRNA.
Two recent studies applied S. Persicae or S. Persicae-
containing formulations (e.g., Fu Zheng Hua Yu recipe)
to the treatment of liver fibrosis [35,36]. Amygdalin in S.
Persicae might be helpful in the treatment of fibrosis, ac-
cording to animal experiments [37]. However, follistatin
has recently emerged as an important therapeutic target
in the treatment of fibrotic diseases for its potent ability
to bind and neutralize activin [14,17,38].Conclusions
Amygdalin isolated from S. Persicae extract in ISF-1
through a bioactivity-guided fractionation procedure in-
duced follistatin expression in HepG2 and C2C12 cell lines.Abbreviations
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